MiR-122 - A key factor and therapeutic target in liver disease

Journal of Hepatology

Volumn 62, Issue 2, 2015, Pages 448-457

  Bandiera, Simonetta ^a,b   Pfeffer, Sébastien ^b,c   Baumert, Thomas F ^a,b,d   Zeisel, Mirjam B ^a,b  

^a Hopitaux Universitaires de Strasbourg   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c INST DE BIOL MOLEC ET CELLULAIRE   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

HBV; HCC; HCV; Liver disease pathogenesis; MiR 122

Indexed keywords

ANTIVIRUS AGENT; MICRORNA 122; MESSENGER RNA; MICRORNA; MIRN122 MICRORNA, HUMAN;

DRUG TARGETING; HEPATITIS B; HEPATITIS C; HOST; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VIRUS CELL INTERACTION; VIRUS HEPATITIS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; LIVER DISEASES; METABOLISM; PROCEDURES;

GENE EXPRESSION REGULATION; GENETIC THERAPY; HUMANS; LIVER DISEASES; MICRORNAS; RNA, MESSENGER;

EID: 84922244588     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.10.004     Document Type: Review

References (126)

1. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404: 293-296.
2. Martinez J, Patkaniowska A, Urlaub H, Lührmann R, Tuschl T. Singlestranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002; 110: 563-574.
3. Kozomara A, Griffiths-Jones S. MiRBase: Integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39: D152-D157.
4. Yang J-S, Lai EC. Dicer-independent, Ago2-mediated microRNA biogenesis in vertebrates. Cell Cycle 2010; 9: 4455-4460.
5. Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol 2013; 14: 475-488.
6. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
7. Bartel DP, Chen C-Z. Micromanagers of gene expression: The potentially widespread influence of metazoan microRNAs. Nat Rev Genet 2004; 5: 396-400.
8. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev 2004; 18: 504-511.
9. Tsang JS, Ebert MS, van Oudenaarden A. Genome-wide dissection of microRNA functions and co-targeting networks using gene set signatures. Mol Cell 2010; 38: 140-153.
10. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
11. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129: 1401-1414.
12. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597-610.
13. Kloosterman WP, Plasterk RHA. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11: 441-450.
14. Bandiera S, Hatem E, Lyonnet S, Henrion-Caude A. MicroRNAs in diseases: From candidate to modifier genes. Clin Genet 2010; 77: 306-313.
15. Hrdlickova B, de Almeida RC, Borek Z, Withoff S. Genetic variation in the non-coding genome: Involvement of micro-RNAs and long non-coding RNAs in disease. Biochim Biophys Acta 2014; 1842: 1910-1922.
16. Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368: 1685-1694.
17. Agostini M, Knight RA. MiR-34: From bench to bedside. Oncotarget 2014; 5: 872-881.
18. Chen Y, Verfaillie CM. MicroRNAs: The fine modulators of liver development and function. Liver Int 2014; 34: 976-990.
19. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013; 10: 542-552.
20. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-739.
21. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. MiR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 2008; 48: 648-656.
22. Hou W, Tian Q, Zheng J, Bonkovsky HL. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 2010; 51: 1494-1504.
23. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011; 6: E23937.
24. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DGN, Antoine DJ, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011; 54: 1767-1776.
25. Waidmann O, Bihrer V, Pleli T, Farnik H, Berger A, Zeuzem S, et al. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat 2012; 19: E58-e65.
26. Van der Meer AJ, Farid WRR, Sonneveld MJ, de Ruiter PE, Boonstra A, van Vuuren AJ, et al. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. J Viral Hepat 2013; 20: 158-166.
27. Köberle V, Waidmann O, Kronenberger B, Andrei A, Susser S, Füller C, et al. Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy. J Viral Hepat 2013; 20: 530-535.
28. Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, et al. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int 2014; 34: E302-e307.
29. Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122, and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 2013; 424: 99-103.
30. Xu H, He J-H, Xiao Z-D, Zhang Q-Q, Chen Y-Q, Zhou H, et al. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 2010; 52: 1431-1442.
31. Laudadio I, Manfroid I, Achouri Y, Schmidt D, Wilson MD, Cordi S, et al. A feedback loop between the liver-enriched transcription factor network and miR-122 controls hepatocyte differentiation. Gastroenterology 2012; 142: 119-129.
32. Deng X-G, Qiu R-L, Wu Y-H, Li Z-X, Xie P, Zhang J, et al. Overexpression of miR-122 promotes the hepatic differentiation and maturation of mouse ESCs through a miR-122/FoxA1/HNF4a-positive feedback loop. Liver Int 2014; 34: 281-295.
33. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009; 28: 3526-3536.
34. Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with "antagomirs". Nature 2005; 438: 685-689.
35. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87-98.
36. Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, Obad S, et al. LNAmediated microRNA silencing in non-human primates. Nature 2008; 452: 896-899.
37. Gatfield D, Le Martelot G, Vejnar CE, Gerlach D, Schaad O, Fleury-Olela F, et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev 2009; 23: 1313-1326.
38. Hsu S-H, Wang B, Kota J, Yu J, Costinean S, Kutay H, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012; 122: 2871-2883.
39. Tsai W-C, Hsu S-D, Hsu C-S, Lai T-C, Chen S-J, Shen R, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012; 122: 2884-2897.
40. Zeisel MB, Pfeffer S, Baumert TF. MiR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. J Hepatol 2013; 58: 821-823.
41. Li J, Ghazwani M, Zhang Y, Lu J, Li J, Fan J, et al. MiR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol 2013; 58: 522-528.
42. Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008; 48: 1810-1820.
43. Coulouarn C, Corlu A, Glaise D, Guénon I, Thorgeirsson SS, Clément B. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res 2012; 72: 2533-2542.
44. Bai S, Nasser MW, Wang B, Hsu S-H, Datta J, Kutay H, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009; 284: 32015-32027.
45. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009; 69: 5761-5767.
46. Zeng C, Wang R, Li D, Lin X-J, Wei Q-K, Yuan Y, et al. A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology 2010; 52: 1702-1712.
47. Nassirpour R, Mehta PP, Yin M-J. MiR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3. PLoS One 2013; 8: E79655.
48. Xu J, Zhu X, Wu L, Yang R, Yang Z, Wang Q, et al. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/b-catenin pathway. Liver Int 2012; 32: 752-760.
49. Nakao K, Miyaaki H, Ichikawa T. Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol 2014; 49: 589-593.
50. Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 2011; 310: 160-169.
51. Hsu S-H, Yu B, Wang X, Lu Y, Schmidt CR, Lee RJ, et al. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Nanomedicine Nanotechnol Biol Med 2013; 9: 1169-1180.
52. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes H-P, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008; 47: 1223-1232.
53. Spaniel C, Honda M, Selitsky SR, Yamane D, Shimakami T, Kaneko S, et al. MicroRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection. PLoS One 2013; 8: E76867.
54. Negrini M, Gramantieri L, Sabbioni S, Croce CM. MicroRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem 2011; 11: 500-521.
55. Imbeaud S, Ladeiro Y, Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis 2010; 30: 75-86.
56. Zeisel MB, Lupberger J, Fofana I, Baumert TF. Host-targeting agents for prevention and treatment of chronic hepatitis C - Perspectives and challenges. J Hepatol 2013; 58: 375-384.
57. Lohmann V. Hepatitis C virus RNA replication. Curr Top Microbiol Immunol 2013; 369: 167-198.
58. Lindenbach BD. Virion assembly and release. Curr Top Microbiol Immunol 2013; 369: 199-218.
59. Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets. Hepatol Int 2011; 5: 644-653.
60. Baumert TF, Meredith L, Ni Y, Felmlee DJ, McKeating JA, Urban S. Entry of hepatitis B and C viruses - Recent progress and future impact. Curr Opin Virol 2014; 4: 58-65.
61. Van der Ree MH, de Bruijne J, Kootstra NA, Jansen PL, Reesink HW. MicroRNAs: Role and therapeutic targets in viral hepatitis. Antivir Ther 2014. http://dx.doi.org/10.3851/IMP2766, [Epub ahead of print].
62. Liu W-H, Yeh S-H, Chen P-J. Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochim Biophys Acta 2011; 1809: 678-685.
63. Shrivastava S, Mukherjee A, Ray RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol 2013; 5: 479-486.
64. Ghosh Z, Mallick B, Chakrabarti J. Cellular versus viral microRNAs in hostvirus interaction. Nucleic Acids Res 2009; 37: 1035-1048.
65. Roberts APE, Lewis AP, Jopling CL. The role of microRNAs in viral infection. Prog Mol Biol Transl Sci 2011; 102: 101-139.
66. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-1581.
67. Villanueva RA, Jangra RK, Yi M, Pyles R, Bourne N, Lemon SM. MiR-122 does not modulate the elongation phase of hepatitis C virus RNA synthesis in isolated replicase complexes. Antiviral Res 2010; 88: 119-123.
68. Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol 2009; 50: 453-460.
69. Chen Y, Shen A, Rider PJ, Yu Y, Wu K, Mu Y, et al. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J 2011; 25: 4511-4521.
70. Zhang G, Li Y, Zheng S, Liu M, Li X, Tang H. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res 2010; 88: 169-175.
71. Bogerd HP, Skalsky RL, Kennedy EM, Furuse Y, Whisnant AW, Flores O, et al. Replication of many human viruses is refractory to inhibition by endogenous cellular microRNAs. J Virol 2014; 88: 8065-8076.
72. Whisnant AW, Bogerd HP, Flores O, Ho P, Powers JG, Sharova N, et al. Indepth analysis of the interaction of HIV-1 with cellular microRNA biogenesis and effector mechanisms. MBio 2013; 4: E000193.
73. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449: 919-922.
74. Hu W, Wang X, Ding X, Li Y, Zhang X, Xie P, et al. MicroRNA-141 represses HBV replication by targeting PPARA. PLoS One 2012; 7: E34165.
75. Zhang X, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, et al. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology 2011; 53: 1476-1485.
76. Ishida H, Tatsumi T, Hosui A, Nawa T, Kodama T, Shimizu S, et al. Alterations in microRNA expression profile in HCV-infected hepatoma cells: Involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem Biophys Res Commun 2011; 412: 92-97.
77. Bhanja Chowdhury J, Shrivastava S, Steele R, Di Bisceglie AM, Ray R, Ray RB. Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. J Virol 2012; 86: 10221-10225.
78. Chen Y, Chen J, Wang H, Shi J, Wu K, Liu S, et al. HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog 2013; 9: E1003248.
79. Wang Y, Lu Y, Toh ST, Sung W-K, Tan P, Chow P, et al. Lethal-7 is downregulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J Hepatol 2010; 53: 57-66.
80. Dai X, Zhang W, Zhang H, Sun S, Yu H, Guo Y, et al. Modulation of HBV replication by microRNA-15b through targeting hepatocyte nuclear factor 1a. Nucleic Acids Res 2014; 42: 6578-6590.
81. Cazalla D, Yario T, Steitz JA, Steitz J. Down-regulation of a host microRNA by a Herpesvirus saimiri noncoding RNA. Science 2010; 328: 1563-1566.
82. Marcinowski L, Tanguy M, Krmpotic A, Rädle B, Lisnic VJ, Tuddenham L, et al. Degradation of cellular mir-27 by a novel, highly abundant viral transcript is important for efficient virus replication in vivo. PLoS Pathog 2012; 8: E1002510.
83. Lu S, Cullen BR. Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J Virol 2004; 78: 12868-12876.
84. Cullen BR. Viruses and microRNAs: RISCy interactions with serious consequences. Genes Dev 2011; 25: 1881-1894.
85. Kincaid RP, Burke JM, Sullivan CS. RNA virus microRNA that mimics a B-cell oncomiR. Proc Natl Acad Sci U S A 2012; 109: 3077-3082.
86. Kincaid RP, Sullivan CS. Virus-encoded microRNAs: An overview and a look to the future. PLoS Pathog 2012; 8: E1003018.
87. Jin W-B, Wu F-L, Kong D, Guo A-G. HBV-encoded microRNA candidate and its target. Comput Biol Chem 2007; 31: 124-126.
88. Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae: The viruses and their replication. Fields Virol., vol. 1. 5th edition, 2007; 1101-52.
89. Jopling CL, Schütz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 2008; 4: 77-85.
90. Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol 2010; 84: 6615-6625.
91. Machlin ES, Sarnow P, Sagan SM. Masking the 50 terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A 2011; 108: 3193-3198.
92. Shimakami T, Yamane D, Welsch C, Hensley L, Jangra RK, Lemon SM. Base pairing between hepatitis C virus RNA and microRNA 122 30 of its seed sequence is essential for genome stabilization and production of infectious virus. J Virol 2012; 86: 7372-7383.
93. Henke JI, Goergen D, Zheng J, Song Y, Schüttler CG, Fehr C, et al. MicroRNA- 122 stimulates translation of hepatitis C virus RNA. EMBO J 2008; 27: 3300-3310.
94. Goergen D, Niepmann M. Stimulation of Hepatitis C Virus RNA translation by microRNA-122 occurs under different conditions in vivo and in vitro. Virus Res 2012; 167: 343-352.
95. Wilson JA, Zhang C, Huys A, Richardson CD. Human Ago2 is required for efficient microRNA 122 regulation of hepatitis C virus RNA accumulation and translation. J Virol 2011; 85: 2342-2350.
96. Conrad KD, Giering F, Erfurth C, Neumann A, Fehr C, Meister G, et al. MicroRNA-122 dependent binding of Ago2 protein to hepatitis C virus RNA is associated with enhanced RNA stability and translation stimulation. PLoS One 2013; 8: E56272.
97. Li Y, Masaki T, Yamane D, McGivern DR, Lemon SM. Competing and noncompeting activities of miR-122 and the 50 exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci U S A 2013; 110: 1881-1886.
98. Narbus CM, Israelow B, Sourisseau M, Michta ML, Hopcraft SE, Zeiner GM, et al. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J Virol 2011; 85: 12087-12092.
99. Kambara H, Fukuhara T, Shiokawa M, Ono C, Ohara Y, Kamitani W, et al. Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. J Virol 2012; 86: 1382-1393.
100. Chang J, Guo J-T, Jiang D, Guo H, Taylor JM, Block TM. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol 2008; 82: 8215-8223.
101. Costa DD, Turek M, Felmlee DJ, Girardi E, Pfeffer S, Long G, et al. Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. J Virol 2012; 86: 11919-11925.
102. Fukuhara T, Kambara H, Shiokawa M, Ono C, Katoh H, Morita E, et al. Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus. J Virol 2012; 86: 7918-7933.
103. Hueging K, Doepke M, Vieyres G, Bankwitz D, Frentzen A, Doerrbecker J, et al. Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. J Virol 2014; 88: 1433-1446.
104. Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL. Reciprocal effects of micro- RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 2007; 133: 1166-1174.
105. Hou W, Bukong TN, Kodys K, Szabo G. Alcohol facilitates HCV RNA replication via up-regulation of miR-122 expression and inhibition of cyclin G1 in human hepatoma cells. Alcohol Clin Exp Res 2013; 37: 599-608.
106. Bukong TN, Hou W, Kodys K, Szabo G. Ethanol facilitates hepatitis C virus replication via up-regulation of GW182 and heat shock protein 90 in human hepatoma cells. Hepatology 2013; 57: 70-80.
107. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009; 15: 31-33.
108. Su T-H, Liu C-H, Liu C-J, Chen C-L, Ting T-T, Tseng T-C, et al. Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proc Natl Acad Sci U S A 2013; 110: 7844-7849.
109. Kamo Y, Ichikawa T, Miyaaki H, Uchida S, Yamaguchi T, Shibata H, et al. Significance of miRNA-122 in chronic hepatitis C patients with serotype 1 on interferon therapy. Hepatol Res 2014. http://dx.doi.org/10.1111/hepr.12317, [Epub ahead of print].
110. Estrabaud E, Lapalus M, Broët P, Appourchaux K, De Muynck S, Lada O, et al. Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. J Virol 2014; 88: 6394-6402.
111. Hildebrandt-Eriksen ES, Aarup V, Persson R, Hansen HF, Munk ME, Orum H. A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys. Nucleic Acid Ther 2012; 22: 152-161.
112. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201.
113. Chung RT, Baumert TF. Curing chronic hepatitis C - The arc of a medical triumph. N Engl J Med 2014; 370: 1576-1578.
114. Trépo C, Chan HLY, Lok A. Hepatitis B virus infection. Lancet 2014; S0140- 6736: 60220-60228.
115. Wang S, Qiu L, Yan X, Jin W, Wang Y, Chen L, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1)-modulated P53 activity. Hepatology 2012; 55: 730-741.
116. Qiu L, Fan H, Jin W, Zhao B, Wang Y, Ju Y, et al. MiR-122-induced downregulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun 2010; 398: 771-777.
117. Li C, Wang Y, Wang S, Wu B, Hao J, Fan H, et al. Hepatitis B virus mRNAmediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. J Virol 2013; 87: 2193-2205.
118. Song K, Han C, Zhang J, Lu D, Dash S, Feitelson M, et al. Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor- gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. Hepatology 2013; 58: 1681-1692.
119. Peng F, Xiao X, Jiang Y, Luo K, Tian Y, Peng M, et al. HBx down-regulated Gld2 plays a critical role in HBV-related dysregulation of miR-122. PLoS One 2014; 9: E92998.
120. Fan C-G, Wang C-M, Tian C, Wang Y, Li L, Sun W-S, et al. MiR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. Oncol Rep 2011; 26: 1281-1286.
121. Wen W, Ding J, Sun W, Fu J, Chen Y, Wu K, et al. Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression. Hepatology 2012; 55: 1787-1798.
122. Forner A, Gilabert M, Bruix J, Raoul J-L. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 2014; 11: 525-535.
123. van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med 2014: E201100899.
124. Lecellier C-H, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C, et al. A cellular microRNA mediates antiviral defense in human cells. Science 2005; 308: 557-560.
125. Lagos D, Pollara G, Henderson S, Gratrix F, Fabani M, Milne RSB, et al. MiR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Nat Cell Biol 2010; 12: 513-519.
126. Umbach JL, Kramer MF, Jurak I, Karnowski HW, Coen DM, Cullen BR. MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature 2008; 454: 780-783.